Navigation Links
VaxGen Issues Rebuttal to MedCap Letter
Date:3/25/2008

cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen and Raven undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Additional Information and Where to Find It

VaxGen has filed a registration statement on Form S-4, and a related proxy statement/prospectus, in connection with the merger. Investors and security holders are urged to read the registration statement on Form S-4 and the related proxy/prospectus (including any amendments or supplements to the proxy statement/prospectus) because they contain important information about the merger transaction. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC at the SEC's web site at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting VaxGen Investor Relations at the email address: ir@vaxgen.com.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

VaxGen, Raven and their respective directors and executive o
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" ... Fourth International Symposium on Thymosins in Health and Disease ... "When thymosin beta 4 (TB4) linked with rhodamine ... cavity in a rodent model of stroke, it was ... parenchyma (the functional tissue of the brain).   The leakage ...
(Date:10/25/2014)... Oct 24, 2014 Research and Markets ... Market by Product , Research Area & by End ... their offering. In this report, the ... products, research areas, and end users. The product segments ... enzymes, instruments & consumables, kits, and reagents. The subsegments ...
(Date:10/22/2014)... , Oct. 22, 2014 New test ... the in vitro diagnostic (IVD) test industry, especially as ... healthcare market researcher listed more than 25 testing innovations ... be the future of IVD products. Kalorama details the new ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... 9 A homegrown New Jersey company is,earning ... of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), a ... an,Honored Finalist as Emerging Business of the Year ... its vision to wipe out counterfeit drugs,worldwide. ...
... Extension Provides Members of University HealthSystem Consortium With Broad ... ... 9 Baxter International,Inc. (NYSE: BAX ) announced today ... signed a new two-year,contract extension on behalf of UHC valued ...
... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTAX) management will present at ... pm at,the Palace Hotel in San Francisco. The conference will also ... webcast can be accessed at, http://www.cticseattle.com . ... BIO CEO & Investor Conference ...
Cached Biology Technology:Secure Symbology: Making New Jersey Proud While Saving Lives 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 3
(Date:10/17/2014)... have shown for the first time how bacteria can ... giving them the opportunity to get tremendous insights into ... study also discovered the bacterial growth in chronic lung ... slowed down by the immune cells. The researchers discovered ... "suffocate" the bacteria, forcing the bacteria to switch to ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... of Virginia researchers have discovered that microRNAs, a form of ... , In the May 1 issue of Genes & ... have shown that microRNAs can suppress the overexpression of a ... fatty tissue and certain tumors, as well as diet-induced obesity. ...
... uncovered evidence that baby fish, only millimetres long, manage to ... of open sea by using their sense of smell. , ... Mike Kingsford of the ARC Centre of Excellence for Coral ... Hole, USA, also shines a new light on how the ...
... of York have won a grant of £110,000 to investigate ... Dr Jason Lynam and Dr Ian Fairlamb, of the University's ... Leverhulme Trust for a three-year study into the use of ... the bloodstream. , Carbon monoxide is an anti-inflammatory, and ...
Cached Biology News:Baby fish 'smell their way home' 2Research to spotlight carbon monoxide benefits 2
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
... a member of a class of proteins who ... sequence. Mut S plays an integral role in ... transcription-coupled nucleotide excision repair and in preventing chromosomal ... binds to DNA specifically at base pair mismatches ...
... Glutathione-S-transferases (GSTs) are a group of enzymes ... xenobiotics in mammals. The enzymes protect cells ... of the glutathione to electrophilic xenobiotics, and ... and toxic effects of the compounds. GST ...
... Monoclonal Antibody Epitope: A ... Recommended Storage: Store vial ... contents and freeze at -20 C or below ... and thawing. Centrifuge product if not completely ...
Biology Products: